A new study published in the journal of The Lancet Neurology showed that candesartan 16 mg used daily is a well-tolerated and effective preventive therapy for episodic migraine.

The angiotensin receptor blocker candesartan has showed promise in modest studies, but there are still few effective and well-tolerated migraine preventative therapies. Thus, this study assessed the safety, tolerability, and effectiveness of candesartan as a preventative measure for episodic migraine.

9 hospitals in Norway and one sizable hospital in Estonia participated in this study. For 12 weeks, adults between the ages of 18 and 64 who experienced 2 to 8 migraine attacks (with or without aura) each month were randomized (1:1:1) to receive oral candesartan 16 mg, candesartan 8 mg, or a placebo every day.

Du

See Full Page